Merck
€134.45Change from previous close: −2.64%Absolute change: −€3.65
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- €58.46B
- Enterprise value
- €69.18B
- P/E (trailing 12 months)
- 24.7
- Forward P/E
- 15.1
- PEG
- 2.22
- Price/book
- 1.93
- Price/sales
- 2.77
- EV/EBITDA
- 12.4
- EV/revenue
- 3.27
Profitability and growth
- Gross margin
- 59.1%
- Operating margin
- 13.9%
- Net margin
- 11.2%
- ROE
- 8.1%
- ROA
- 4.7%
- ROIC
- 7.6%
- Revenue growth (year over year)
- 3.4%
- Earnings growth (year over year)
- -24.7%
Financial health
- Total cash
- €3.12B
- Total debt
- €12.3B
- Debt/equity
- 0.41
- Current ratio
- 1.70
- Quick ratio
- 0.99
- Altman Z-Score
- 2.79
- Piotroski F-Score
- 6.00
Dividends
- Annual dividend per share
- €2.20
- Dividend yield
- 1.6%
- Payout ratio
- 40.4%
- Ex-dividend date
- April 27, 2026
Analysts and estimates
- Average price target
- €154.21
- Median price target
- €152.50
- High price target
- €179.00
- Low price target
- €135.00
- Number of analysts
- 14
- Consensus
- Buy
- Forward EPS
- €8.91
- EPS estimate, current year
- €8.42
Shares and trading
- Beta
- 0.81
- Average volume
- 267.53K
- Shares outstanding
- 129.24M
- Float
- 128.87M
- Institutional ownership
- 57.0%
- Insider ownership
- 0.0%